Another target is the B-cell maturation antigen (BCMA), which is thought to be involved in all stages of B-cell differentiation and maturation and is highly expressed in myeloma cells; therefore, it is considered a better target in CAR-T cell therapy (Ali et al., 2016). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.